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MACEAbstract Background: Cardiovascular disease is the leading cause of death in Egypt and
worldwide, placing great strain on the world’s health systems. This is one of the few Egyptian
registries dealing with patients with acute coronary syndrome admitted in critical care department,
Cairo University.
Methods: This is a retrospective non-controlled cohort study of patients with acute coronary
syndrome admitted from January 2010 to December 2012. Retrospective analysis of these patients
data were retrieved through reviewing written paper and electronic database.
Results: A total number of 503 patients were enrolled in our study. The mean age was 57.2
± 10.4 years. Their pain duration was 14 ± 24.4 h. Average length of stay was (7 ± 4.4 days).
Primary percutaneous coronary intervention (PCI) was done to 154 patients (30.6%), while we
had 105 elective PCI procedures (20.9%). Major adverse cardiac events (MACE) were higher in
patients with higher age (60 years vs 56.7 years P value 0.021), STEMI (25.7% vs. 18% in UA/
NSTEMI P value 0.002), higher CKMB levels (157iu/l vs 89iu/l P value0.019), and higher Killip
class upon presentation (class III-IV 64.9% vs 2.2% class I-II p< 0.001). Patients with UA/
NSTEMI who were treated conservatively developed statistically significant higher incidence of
MACE as compared to those treated interventionally (23.4% vs. 13.5% P value 0.031). Patients
with STEMI who were treated without intervention have significant higher incidence of MACE
than those who were treated interventionally (15.4% vs. 5.5% p = 0.46).
Conclusion: 1. Higher incidence of MACE was observed in the higher age group, higher levels of
cardiac biomarkers, and higher Killip class. 2. Outcome was affected by early interventional treat-
ment in all patient groups.
 2016 The Egyptian College of Critical Care Physicians. Production and hosting by Elsevier B.V. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Effective treatment of acute coronary syndrome (ACS)
requires a highly functioning health care delivery system,
driven by valid, reliable measurement for continuous improve-
ment. Registries have been used to identify concrete practices
associated with improved patient outcomes, identify
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and quantifying racial and socioeconomic disparities in both
treatment patterns and health outcomes. Systematic collection
of data on health outcomes is a fundamental first step toward
strengthening hospital care, and might be especially helpful in
low and middle income countries (LMICs), where resource
constraints are a major concern. Registries provide both
evidence for the design and prioritization of improvement
strategies and a means to evaluate the effects of strategies after
implementation. Any study should describe the challenges and
opportunities identified through the ACS course with a focus
on the lessons learned through the process of registry develop-
ment and operationalization [1,2].2. Aim of the work
The aim of the work was to determine our local performance
in the management of acute coronary syndrome patients either
treated by conservative or invasive strategy and to find out
clinical or procedural risk factors that could result in poor out-
come in terms of high major adverse cardiac events and mor-
tality rates.3. Patients and methods
The material of the registry included 503 patients who were
admitted to the Critical Care Department, Cairo University
with ACS between January 2010 and December 2012. Patient
data were retrieved through reviewing written papers and elec-
tronic database i.e. patients’ files, and reviewing PCI reports.
Data collection was focused on patients’ demographics, risk
factors for CAD, percutaneous coronary intervention indica-
tions, baseline clinical status and Killip class [3] & associated
medical conditions, angiographic & PCI procedure details,
angiographic & clinical Success of PCI procedure, in-hospital
MACE (Major Adverse Cardiovascular Events), Risk factors
associated with poor outcomes for in-hospital complications
and MACE. Inclusion criteria were: all patients diagnosed to
have ACS [A spectrum of clinical conditions characterized
by acute chest pain or myocardial ischemia. ACS includes
myocardial infarction with ST-segment Elevation (STEMI),
myocardial infarction in the absence of ST-Segment Elevation
(NSTEMI) and unstable angina]. An initial clinical subdivision
of ACS is made on the presence or absence of ECG
ST-segment Elevation. All clinical events were reviewed and
documented. The clinical end points were the in hospital
MACE defined as the composite of death, myocardial infarc-
tion [ST elevation MI (STEMI) and non ST elevation MI
(NSTEMI)], need for Revascularization: PCI or CABG for
previously vascularized patients.
3.1. Statistical methods
Data were verified and coded prior to analysis; all quantitative
data were expressed as mean ± SD. All qualitative data were
expressed as frequency tables. Chi-Square test was used to con-
firm the presence of association between different categorical
data. Student- t test was used to compare between quantitative
data.To better understand the predictors of mortality, two anal-
yses of multiple logistic regression models were performed: one
to identify demographic factors and associated in-hospital
interventions, and another to identify the influence of major
complications on death. P value < 0.05 was considered signif-
icant. Analysis has been performed using SPSS (statistical
package for social science).
4. Results
4.1. Baseline demographic,clinical and laboratory data
(Table 1)
A total number of 503 patients were enrolled in our registry.
The study included 381 males (75.7%), 122 females (24.3%)
with a mean age 57.2 ± 10.4 years. Their mean chest pain
duration was 14 ± 24.4 h. Average length of stay was 7
± 4.4 days. Of the total number of patients, 301 patients were
diagnosed as UA/NSTEMI (60%) [171 patients (34%) had
UA and 130 patients (26%) had NSTEMI] and 202 patients
as STEMI cases (40%).
Hypertension was the most prevalent risk factor (57.3%),
followed by smoking (52.1%) then diabetes (49.9%) and dys-
lipidemia(23.7%).We did not find any statistically significant
difference between the two study groups (STEMI&UA/
NSTEMI) regarding the prevalence of Diabetes mellitus
(p 0.27), family history of CAD (p 0.52) or dyslipidemia
(p 0.32) yet there was a statistically significant difference
between the 2 groups as regards the prevalence of Hyperten-
sion (p< 0.001),incidence of smoking (p< 0.001) & past his-
tory of CAD (p< 0.001).
Concerning the baseline hemodynamic parameters, we
found a statistically significant lower mean systolic blood pres-
sure (SBP), lower mean diastolic blood pressure (DBP), lower
mean arterial pressure (MAP) in the STEMI group when com-
pared to UA/NSTEMI group, yet there was no statistically sig-
nificant difference between the two groups regarding mean
HR. There was a statistically significant higher Killip class in
STEMI group compared to UA/NSTEMI group. (1.5 ± 1.1
vs. 1.4 ± 0.8 p value 0.033).
4.2. Procedural data (Table 2)
Out of the 503 patients included in our registry, 259 (51.5%)
patients were managed interventionally and 244 (48.5%)
patients were managed conservatively. Of those patients who
were treated conservatively, thirty-nine patients were admitted
with STEMI (16%) and 205 patients with UA/NSTEMI
(84%).The thirty-nine STEMI patients didn’t have interven-
tional treatment during their icu stay due to one of the follow-
ing causes: Successful thrombolytic therapy, delayed
presentation, or death shortly after presentation. Throm-
bolytic therapy was used in 20 patients; seven out of them were
diagnosed as thrombolytic therapy failed cases, so they were
subjected to early coronary intervention. Primary intervention
was done in the 1st day while delayed interventions were done
within 7.1 ± 0.7 days. Seventy patients were planned for
CABG (13.9%). There were 905 vessels with1216 affected seg-
ments in the studied patients & not all lesions were subjected to
PCI trial. Untreated segments were either of small calibers,
Table 1 Baseline demographic, clinical and laboratory data.
UA/NSTEMI (301 pts.) STEMI (202 pts.) P value
Number Percentage Number Percentage
Sex <0.001
Female 96 32% 26 13%
Male 205 68% 176 87%
Family history of CAD 90 30% 60 30% 0.522
Smoking 132 44% 130 64% <0.001
Diabetes 150 50% 81 40% 0.27
Hypertension 222 74% 66 33% <0.001
Dyslipidemia 72 24% 44 22% 0.327
Past history of CAD 173 57.5% 74 36.6% <0.001
Mean SD Mean SD
Chest Pain duration 15.0 25.9 12.3 22.0 0.219
SBP 137.7 29.6 124.1 25.4 <.001
DBP 82.8 15.9 75.6 15.9 <.001
MAP 100.6 20.7 91.8 18.4 <.001
HR 84.8 17.1 85.0 19.9 0.896
Killip class 1.4 .8 1.5 1.1 0.033
CPK (u/l) 421.4 592.9 2122.2 1297.2 <.001
CKMB (u/l) 48.7 57.9 295.6 276.2 <.001
Troponin 0.5 0.5 1.0 .0 <.001
Cardiac enzymes peaking (hours after presentation) 14.1 10.4 8.3 5.8 <.001
Retrospective analysis of acute coronary syndrome 81surgically bypassed in post-CABG patients, located in distal
segments or with less than 50–60% stenosis and with no evi-
dence of active ischemia in ECG or Echocardiography, so
the targeted lesions in this study were 308 lesions in 303 vessels.
Single vessel disease was present in 90 patients (34.8%), two
vessel disease was present in 92 patients (35.5%) while multi-
vessel disease was present in 77 patients (29.7%). The most
prevalent diseased segment was proximal LAD (14.9%), fol-
lowed by Mid LAD (13.9%) then proximal RCA (11.9%).
Out of the total number of studied patients, 211 patients
(41.9%) received 235 bare metal stents (BMS) stents (143
patients had primary PCI, 68 patients had elective PCI). Forty
patients (8%) received 52 drug eluting stents (DES) (7 patients
had primary PCI, 33 patients had elective PCI). There were 8
patients (1.2%) who received both BMS & DES stents (18
stents). There was a statistically significant higher incidence
of BMS implantation in primary PCI (in STEMI) and early
invasive strategy (in NSTEMI) while in elective PCI there
was a statistically significant higher incidence of DES implan-
tation (p value < 0.001) .ICU stay was nearly similar in the
BMS & DES groups.
4.3. Post-procedure complication and immediate outcome
(Table 3)
 Restoring TIMI flow III after the PCI procedure was
achieved in 98.4% of the included patients in our registry.
Procedural complications were analyzed, taking into
account that not all patients were subjected to cardiac inter-
vention i.e. 259 out of 503 patients. Procedural complica-
tions occurred in 6.9%. Clinical success of PCI procedure
was defined as accomplishing PCI procedure with no in-
hospital MACE. Clinical success was achieved in 70.1%
of cases underwent PCI.4.4. IV-Outcome data (Table 4)
4.4.1. Major adverse cardiac events (MACE)
Patients with MACE were significantly older than those with-
out MACE, (59.7 ± 9.5 years vs 56.7 ± 10 years P value
0.021). Using univariate regression analysis, each year increase
in age increases odds of experiencing MACE by 3%, (P value
0.021). Patients with UA/NSTEMI who were treated conser-
vatively developed statistically significant higher incidence of
MACE compared to those treated interventionally (23.4%
vs. 13.5% P value 0.031). Patients with STEMI who were trea-
ted without intervention have statistically significant higher
incidence of MACE than those who were treated intervention-
ally (15.4% vs. 5.5% P value 0.046).
Patients who experienced in hospital MACE had higher
baseline levels of CK-MB, compared to those free of MACE,
(157.7 ± 229 u/l vs. 89.5± 116.6 u/l P value 0.019). Regarding
those who underwent PCI, patients who experienced procedu-
ral complications had higher in hospital MACE rates than
those who were free of any procedural complications,
(66.7% vs 16.1 P value < 0.001).
4.4.2. Mortality
Patients who experienced STEMI had higher mortality rates
compared to NSTEMI/UA, (16.8% vs. 4.3% P value 0.003).
Patients with poor clinical status as assessed by Killip class
(class III–IV) had significantly higher mortality rates than
those with lower Killip class (I–II). (64.9% vs 2.2% p
value < 0.001).
Irrespective of the clinical diagnosis on admission, patients
who died were older but the age difference was not statistically
significant (59.98 ± 7.9 years vs 56.9 ± 10.5 years P-value
Table 2 Procedural data.
Parameter Value
All patients subjected to PCI 259 patients
(51.5%)
Primary PCI 154 patients
(30.6%)
Elective PCI 105 patients
(20.9%)
Number of diseased vessels
Single vessel disease 90 patients (34.8%)
Two vessel disease 92 patients (35.5%)
Multivessel disease 77 patients (29.7%)
The diseased vessel segment
Proximal LAD 14.9%
Mid LAD 13.9%
Proximal RCA 11.9%
Mid RCA 9.5%
Proximal LCX 8.9%
Mid LCX 4.8%
Distal RCA 3.2%
Ostial LAD 2.4%
Distal LAD 1.9%
Major side branch (diagonal, OM, PL,
PDA)
28.6%
Types of stents
Bare metal stents (BMS) 211 patients
(81.5%)
Drug eluting stents (DES) 40 patients (15.4%)
Both (BMS & DES) 8 patients (3.1%)
Bare metal stents 211 patients
Primary PCI 143 patients
(67.8%)
Elective PCI 68 patients (32.2%)
Drug eluting stents 40 patients
Primary PCI 7 patients (17.5%)
Elective PCI 33 patients (82.5%)
ICU stay
BMS group 7 ± 3.8 days
DES group 6.9 ± 2.9 days
Table 3 Post-procedure complications & immediate outcome.
Parameter Value
Angiographic success 98.4%
TIMI 0 0.4%
TIMI 1 0.4%
TIMI 2 0.8%
TIMI 3 98.4%
Clinical success 70.1%
Procedural complication 6.9%
Coronary dissection 0.8%
Distal embolization 0.8%
Failed PCI 2.3%
No reflow 1.5%
Acute stent thrombosis 1.1%
Dye induced nephropathy 0.4%
Major adverse cardiac event 29.9%
Death 38 patients (14.7%)
MI 3 patients (1.2%)
Unstable angina 2 patients (0.8%)
Cardiogenic shock 31 patients (12%)
Fatal ventricular dysrhythmias 1 patient (0.4%)
Target vessel revascularization 2 patients (0.8%)
Table 4 outcome (MACE & Mortality) data.
Parameter MACE No MACE P value
Age (years) 59.7 ± 9.5 56.7 ± 10.4 0.021
CK-MB(u/l) 157 ± 229 89 ± 116.6 0.019
Procedural complications 66.7% 33.3% <.001
No complications 16.1% 83.9%
Parameter Survivors Non-survivors P value
Age (years) 56.9 ± 10.5 59.98 ± 7.9 0.054
ACS
STEMI 83.2% 16.8% 0.003
UA/NSTEMI 95.7% 4.3%
Killip class
1–2 97.8% 2.2% <0.001
3–4 35.1% 64.9%
MAP (mmHg) 99.2 ± 18.8 75.7 ± 21.5 <0.001
EF % 56 46.5 <0.001
82 H. Tawfeek et al.0.054). Non survivors had statistically significant lower admis-
sion MAP compared to those who survived. (75.7 mmHg vs
99.2 mmHg – P value < 0.001). Also non survivors had statis-
tically significant lower ejection fraction (EF) when compared
to those who survived. (46.5% vs 56.0% – P value < 0.001).
Using multivariate analysis to determine predictors of mortal-
ity, it showed that the best predictors were MAP, diagnosis of
STEMI and Killip class > 2. Each unit increase in MAP
decreased odds of mortality, rendering this state 4% less likely,
while Killip class above 2 increased odds of mortality and ren-
dering this state 73.4 times more likely. Also, diagnosis of
STEMI increased odds of mortality and rendering this state
2.8 times more likely than UA/NSTEMI.
5. Discussion
In the current registry, the mean age of the studied patients
was 57.2 ± 10.4 years; this was lower than that stated by
Granger et al. (GRACE registry), who found that the mean
age was 66.3 years. Also Puymirat, E & co-workers found thatthe mean age in their registry (Euro Heart survey) was 66
± 13 years, Chin et al., found that mean age was 64 years in
the ACTION Registry – Get With The Guidelines (GWTG),
and similarly Daida et al., found that the mean age was
67 years in the PACIFIC Registry [4–7]. This age discrepancy
between our registry and the previously mentioned registries
could be explained by the higher prevalence of risk factors of
CAD among Egyptian population especially Diabetes mellitus.
Hypertension was the most common risk factor encoun-
tered in our registry (57.2%). This result was concordant with
Ibrahim, who concluded that hypertension is common among
Egyptian population and that 26.3% of adult Egyptians had
high blood pressure in the years from 1991 to 1993. He stated
that more than 50% of individuals older than 60 years suffered
from hypertension [8]. In our registry, 45.9% of patients were
diabetics and this was significantly higher than that encoun-
tered in GRACE (23.3%) [4], ACTION (29.5%)[6], EHS
Retrospective analysis of acute coronary syndrome 83(24%)[5], PACIFIC (35%) [7] registries. Our results go hand in
hand with the postulation by Shaw et al. who stated that
between 2010 and 2030, there will be 69% increase in the num-
ber of adults with diabetes in developing countries and 20%
increase in developed countries. Egypt will have at least 8.6
million adults with diabetes [9]. This would explain the higher
prevalence of diabetes in our registry compared to the interna-
tional registries.
In the current registry, 76.2% of the STEMI group had pri-
mary intervention on the day of admission. We had signifi-
cantly higher rate of primary PCI than the GRACE registry
in which Fox et al. found that 40% of STEMI population
underwent PCI of which 18% was primary PCI [10], the
EHS in which Puymirat et al. found that 50% had primary
PCI [5], GULF registry in which Zubaid found that primary
PCI was done in only 7%.[11].
Among patients who underwent PCI, angiographic success
was achieved in 98.4%, procedural complications occurred in
6.9% and clinical success was achieved in 70.1% of cases.
Patients who experienced procedural complications had higher
in hospital MACE rates than those who were free of any pro-
cedural complications (66.7% vs 16.1% P value < 0.001). Our
Angiographic success rate was concordant with Shaikh et al.,
who found that PCI success rate was 97%, Prashanth et al.
who stated that the angiographic success rate was 98% [12,13].
We also agree with Pride et al., who found that the occur-
rence of procedural complications was associated with worse
clinical outcome. (P< 0.001). [14] The reported success rate
in our registry was higher than that encountered by Buller
et al. in the Occluded Artery Trial, they stated that the inci-
dence of successful PCI procedures was 87%. We disagree with
them as they stated that PCI failure didn’t significantly affect
outcome, this difference may be due to recruitment of stable
myocardial infarction survivors with persistent infarct-related
artery occlusion identified during days 3 to 28 post MI in their
trial compared to inclusion of only acute coronary syndrome
patients (STEMI or UA/NSTEMI in our registry) [15].
In our registry, we found that overall mortality rate was
7.6% (38 out of 503 included patients). Higher mortality was
associated with STEMI compared to UA/NSTEMI (16.8%
vs. 4.3%, P value = 0.003), higher Killip class (64.9% in Killip
class III/IV vs 2.2% in Killip class I/II P value < 0.001), lower
MAP at presentation (75.7 vs 99.2 mmHg P value < 0.001) &
lower EF (46.5 vs 56% P value < 0.001). Mortality was also
higher in older patients but this was statistically insignificant
(59.9 vs 56.9 P value = 0.054). Granger et al., collected data
from the GRACE found eight predictors of mortality which
were age, Killip class, systolic blood pressure (SBP), ST seg-
ment deviation, cardiac arrest during presentation, high serum
creatinine level, positive initial cardiac enzyme finding and
heart rate. Their overall mortality was 4.5% [4]. In contrast
to our registry; they found that age was a strong predictor of
mortality. This difference may be due to relatively young
patient population in our registry compared to their registry
(57 years vs 66 years). Granger et al., found that mortality
was higher in patients with ST deviation [4] while we found
that only ST elevation is the ECG change that was associated
with higher mortality, this difference may be attributed to the
relatively small number of patients presented with ST depres-
sion (NSTEMI) in our registry compared to their registry
(26% vs. 33%), and higher incidence of ST elevation(STEMI)
in our registry compared to their registry (40% vs. 35.3%).6. Conclusion
Higher prevalence of risk factors for CAD could possibly
explain younger age of our subjects in comparison to other
registries. Primary PCI is the reperfusion strategy of choice
in STEMI patients in our center. Our success rate of PCI pro-
cedures matches the international rates. MACE was higher in
older patients, patients with higher initial cardiac CK-MB,
those who developed procedural complication; those who trea-
ted conservatively. Predictors of mortality were diagnosis of
STEMI, higher Killip class and lower MAP.
Recommendation
Despite being a single center retrospective study, understand-
ing the findings of this study may help in mapping our incon-
sistencies and improving the planning of a larger multicentric
prospective randomized controlled study for better description
of the Egyptian profile of those patients with acute coronary
syndrome in order to improve their public level of care.
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